Patents by Inventor Ganesh Kaundinya

Ganesh Kaundinya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods For The Treatment Of Neurodegeneration
    Publication number: 20220267413
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or a 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Application
    Filed: May 9, 2022
    Publication date: August 25, 2022
    Inventors: Thomas E. Prod`Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Methods for the treatment of neurodegeneration
    Patent number: 11352415
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 7, 2022
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Methods Related to Alemtuzumab
    Publication number: 20200354465
    Abstract: The present invention relates to the characterization and production of alemtuzumab.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Methods For The Treatment Of Neurodegeneration
    Publication number: 20200055921
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 20, 2020
    Inventors: Thomas E. Prod`Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Methods for the treatment of neurodegeneration
    Patent number: 10464996
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 5, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Methods related to CTLA4-Fc fusion proteins
    Patent number: 10450361
    Abstract: The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: October 22, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Xiaomei He, Yan Yin, Yin Yin Lin, Brian Collins, Jennifer Murphy, Ganesh Kaundinya
  • METHODS RELATED TO ADALIMUMAB
    Publication number: 20190077857
    Abstract: The present invention relates to the characterization and production of adalimumab.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 14, 2019
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS OF EVALUATING AND MAKING BIOLOGICS
    Publication number: 20190079101
    Abstract: Methods of making and evaluating biologic therapeutic products are disclosed.
    Type: Application
    Filed: April 9, 2018
    Publication date: March 14, 2019
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Methods related to denosumab
    Patent number: 9695244
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: July 4, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS
    Publication number: 20160097074
    Abstract: The invention provides methods, databases and systems for making glycoprotein products having defined properties.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 7, 2016
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Carlos J. Bosques, Lakshmanan Thiruneelakantapillai, Dorota A. Bulik, Ian C. Parsons, Zachary Shriver, Rajeev Chillakuru, Ganesh Kaundinya
  • METHODS FOR THE TREATMENT OF NEURODEGENERATION
    Publication number: 20160090409
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Application
    Filed: May 13, 2014
    Publication date: March 31, 2016
    Inventors: Thomas E. PROD'HOMME, Leona E. LING, Carlos J. BOSQUES, Anthony MANNING, Ganesh KAUNDINYA
  • METHODS RELATED TO CTLA4-FC FUSION PROTEINS
    Publication number: 20150368317
    Abstract: The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 24, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John ROBBLEE, Xiaomei HE, Yan YIN, Yin Yin LIN, Brian COLLINS, Jennifer MURPHY, Ganesh KAUNDINYA
  • Saccharide structures and methods of making and using such structures
    Patent number: 9163047
    Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 20, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Sucharita Roy, Takashi Kei Kishimoto, Ganesh Kaundinya
  • METHODS RELATED TO DENOSUMAB
    Publication number: 20150246974
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: September 3, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS OF EVALUATING AND MAKING BIOLOGICS
    Publication number: 20150204884
    Abstract: Methods of making and evaluating antibody biological therapeutics (biosimilars) for adalimumab, rituximab and panitumumab are disclosed.
    Type: Application
    Filed: May 31, 2013
    Publication date: July 23, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO ADALIMUMAB
    Publication number: 20150158943
    Abstract: Production and bioanalytical characterization of determinative parameters of adalimumab is presented.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 11, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO PANITUMUMAB
    Publication number: 20150152184
    Abstract: The present invention relates to the characterization and production of panitumumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 4, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO BEVACIZUMAB
    Publication number: 20150147317
    Abstract: The present invention relates to the characterization and production of bevacizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO RITUXIMAB
    Publication number: 20150141620
    Abstract: The present invention relates to the characterization and production of rituximab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO OMALIZUMAB
    Publication number: 20150140608
    Abstract: The present invention relates to the characterization and production of omalizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques